Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - Reck, M; Kaiser, R; Mellemgaard, A (Lancet Oncol, 2014)
, et al; LUME-Lung 1 Study Group.